全文获取类型
收费全文 | 15530篇 |
免费 | 983篇 |
国内免费 | 73篇 |
专业分类
耳鼻咽喉 | 78篇 |
儿科学 | 589篇 |
妇产科学 | 383篇 |
基础医学 | 2149篇 |
口腔科学 | 311篇 |
临床医学 | 1508篇 |
内科学 | 3307篇 |
皮肤病学 | 385篇 |
神经病学 | 1630篇 |
特种医学 | 400篇 |
外科学 | 1620篇 |
综合类 | 86篇 |
一般理论 | 16篇 |
预防医学 | 1187篇 |
眼科学 | 295篇 |
药学 | 1059篇 |
中国医学 | 24篇 |
肿瘤学 | 1559篇 |
出版年
2023年 | 158篇 |
2022年 | 121篇 |
2021年 | 469篇 |
2020年 | 322篇 |
2019年 | 460篇 |
2018年 | 506篇 |
2017年 | 390篇 |
2016年 | 404篇 |
2015年 | 499篇 |
2014年 | 643篇 |
2013年 | 853篇 |
2012年 | 1297篇 |
2011年 | 1236篇 |
2010年 | 732篇 |
2009年 | 619篇 |
2008年 | 1056篇 |
2007年 | 1069篇 |
2006年 | 1001篇 |
2005年 | 920篇 |
2004年 | 871篇 |
2003年 | 828篇 |
2002年 | 665篇 |
2001年 | 116篇 |
2000年 | 97篇 |
1999年 | 125篇 |
1998年 | 99篇 |
1997年 | 83篇 |
1996年 | 70篇 |
1995年 | 68篇 |
1994年 | 62篇 |
1993年 | 64篇 |
1992年 | 76篇 |
1991年 | 64篇 |
1990年 | 46篇 |
1989年 | 38篇 |
1988年 | 42篇 |
1987年 | 48篇 |
1986年 | 30篇 |
1985年 | 33篇 |
1984年 | 36篇 |
1983年 | 24篇 |
1982年 | 20篇 |
1981年 | 17篇 |
1980年 | 20篇 |
1979年 | 22篇 |
1978年 | 17篇 |
1969年 | 13篇 |
1968年 | 19篇 |
1967年 | 12篇 |
1966年 | 12篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Nicla La Verde Agostino Riva Maria Silvia Cona Arianna Gabrieli Monica Cattaneo Cinzia Fasola Giuseppe Lipari Claudia De Stradis Valentina Favorito Benedetta Lombardi Stocchetti Davide Chizzoniti Alice Covizzi Eliana Rulli Francesca Galli Lorenzo Ruggieri Anna Gambaro Sabrina Ferrario Davide Dalu Maciej S. Tarkowski 《International journal of cancer. Journal international du cancer》2023,152(4):661-671
Previous studies on the immunogenicity of SARS-CoV-2 mRNA vaccines showed a reduced seroconversion in cancer patients. The aim of our study is to evaluate the immunogenicity of two doses of mRNA vaccines in solid cancer patients with or without a previous exposure to the virus. This is a single-institution, prospective, nonrandomized study. Patients in active treatment and a control cohort of healthy people received two doses of BNT162b2 (Comirnaty, BioNTech/Pfizer, The United States) or mRNA-1273 (Spikevax, Moderna). Vaccine was administered before starting anticancer therapy or on the first day of the treatment cycle. SARS-CoV-2 antibody levels against S1, RBD (to evaluate vaccine response) and N proteins (to evaluate previous infection) were measured in plasma before the first dose and 30 days after the second one. From January to June 2021, 195 consecutive cancer patients and 20 healthy controls were enrolled. Thirty-one cancer patients had a previous exposure to SARS-CoV-2. Cancer patients previously exposed to the virus had significantly higher median levels of anti-S1 and anti-RBD IgG, compared to healthy controls (P = .0349) and to cancer patients without a previous infection (P < .001). Vaccine type (anti-S1: P < .0001; anti-RBD: P = .0045), comorbidities (anti-S1: P = .0274; anti-RBD: P = .0048) and the use of G-CSF (anti-S1: P = .0151) negatively affected the antibody response. Conversely, previous exposure to SARS-CoV-2 significantly enhanced the response to vaccination (anti-S1: P < .0001; anti-RBD: P = .0026). Vaccine immunogenicity in cancer patients with a previous exposure to SARS-CoV-2 seems comparable to that of healthy subjects. On the other hand, clinical variables of immune frailty negatively affect humoral immune response to vaccination. 相似文献
2.
3.
Paul G. Richardson Fredrik Schjesvold Katja Weisel Philippe Moreau Larry D. Anderson Darrell White Paula Rodriguez-Otero Pieter Sonneveld Monika Engelhardt Matthew Jenner Alessandro Corso Jan Dürig Michel Pavic Morten Salomo Meral Beksac Albert Oriol Jindriska Lindsay Anna Marina Liberati Monica Galli Pawel Robak Alessandra Larocca Munci Yagci Filiz Vural Abraham S. Kanate Ruiyun Jiang Lara Grote Teresa Peluso Meletios Dimopoulos 《European journal of haematology》2022,108(1):73-83
4.
5.
Susanna Zanutto Chiara Maura Ciniselli Antonino Belfiore Mara Lecchi Enzo Masci Gabriele Delconte Massimo Primignani Giulia Tosetti Marco Dal Fante Linda Fazzini Aldo Airoldi Marcello Vangeli Francesca Turpini Giovanni Giuseppe Rubis Passoni Paolo Viaggi Monica Arena Roberta Ilaria Olimpia Motta Anna Maria Cantù Cristiano Crosta Giuseppe De Roberto Francesca Iannuzzi Andrea Cassinotti Valentina Dall'Olio Laura Tizzoni Gabriella Sozzi Emanuele Meroni Luigi Bisanti Marco Alessandro Pierotti Paolo Verderio Manuela Gariboldi 《International journal of cancer. Journal international du cancer》2020,146(4):1164-1173
Colorectal cancer (CRC) screening programs help diagnose cancer precursors and early cancers and help reduce CRC mortality. However, currently recommended tests, the fecal immunochemical test (FIT) and colonoscopy, have low uptake. There is therefore a pressing need for screening strategies that are minimally invasive and consequently more acceptable to patients, most likely blood based, to increase early CRC identification. MicroRNAs (miRNAs) released from cancer cells are detectable in plasma in a remarkably stable form, making them ideal cancer biomarkers. Using plasma samples from FIT-positive (FIT+) subjects in an Italian CRC screening program, we aimed to identify plasma circulating miRNAs that detect early CRC. miRNAs were initially investigated by quantitative real-time PCR in plasma from 60 FIT+ subjects undergoing colonoscopy at Fondazione IRCCS Istituto Nazionale dei Tumori, then tested on an internal validation cohort (IVC, 201 cases) and finally in a large multicenter prospective series (external validation cohort [EVC], 1121 cases). For each endoscopic lesion (low-grade adenoma [LgA], high-grade adenoma [HgA], cancer lesion [CL]), specific signatures were identified in the IVC and confirmed on the EVC. A two-miRNA-based signature for CL and six-miRNA signatures for LgA and HgA were selected. In a multivariate analysis including sex and age at blood collection, the areas under the receiver operating characteristic curve (95% confidence interval) of the signatures were 0.644 (0.607–0.682), 0.670 (0.626–0.714) and 0.682 (0.580–0.785) for LgA, HgA and CL, respectively. A miRNA-based test could be introduced into the FIT+ workflow of CRC screening programs so as to schedule colonoscopies only for subjects likely to benefit most. 相似文献
6.
Javad Sharifi‐Rad Shahira M. Ezzat Mahitab H. El Bishbishy Dima Mnayer Farukh Sharopov Ceyda S. Kl Monica Neagu Carolina Constantin Mehdi Sharifi‐Rad Maria Atanassova Silvana Nicola Giuseppe Pignata Bahare Salehi Patrick V. T. Fokou Natlia Martins 《Phytotherapy research : PTR》2020,34(7):1474-1518
Rosmarinus species are aromatic plants that mainly grow in the Mediterranean region. They are widely used in folk medicine, food, and flavor industries and represent a valuable source of biologically active compounds (e.g., terpenoids, flavonoids, and phenolic acids). The extraction of rosemary essential oil is being done using three main methods: carbon dioxide supercritical extraction, steam distillation, and hydrodistillation. Furthermore, interesting antioxidant, antibacterial, antifungal, antileishmanial, anthelmintic, anticancer, anti‐inflammatory, antidepressant, and antiamnesic effects have also been broadly recognized for rosemary plant extracts. Thus the present review summarized data on economically important Rosmarinus officinalis species, including isolation, extraction techniques, chemical composition, pharmaceutical, and food applications. 相似文献
7.
Ribeiro Monica Durand Thomas Roussel Martine Feuvret Loïc Jacob Julian Psimaras Dimitri Noel Georges Keller Audrey Bompaire Flavie Hoang-Xuan Khê Bernier Marie-Odile Godefroy Olivier Ricard Damien 《Journal of neuro-oncology》2020,148(2):335-342
Journal of Neuro-Oncology - Cognitive impairment is frequent in patients with high-grade glioma and requires cognitive follow-up. Cognitive screening tools such as the Montreal Cognitive Assessment... 相似文献
8.
9.
Jennifer Milucky Maria de Gloria Carvalho Nadine Rouphael Nancy M. Bennett H.Keipp Talbot Lee H. Harrison Monica M. Farley Jeremy Walston Fabiana Pimenta Fernanda C. Lessa 《Vaccine》2019,37(8):1094-1100
Background
Vaccination of children with 13-valent pneumococcal conjugate vaccine (PCV13) led to declines in vaccine-type pneumococcal nasopharyngeal carriage among adults through indirect effects. In August 2014, PCV13 immunization of all U.S. adults ≥65?years of age was recommended. This study sought to define prevalence and serotype distribution of pneumococcal carriage among adults ≥65?years of age and to describe risk factors for colonization soon after introduction of PCV13 in adults.Methods
A cross-sectional survey of non-institutionalized U.S. adults ≥65?years of age was conducted in four states in 2015–2016. Demographic information, risk factors for disease, PCV13 vaccination history, and nasopharyngeal (NP) and oropharyngeal (OP) swabs were collected. NP and OP swabs were processed separately and pneumococcal isolates were serotyped by Quellung reaction. Antimicrobial susceptibility of pneumococcal isolates was performed. NP swabs also underwent real-time PCR for pneumococcal detection and serotyping.Results
Of 2989 participants, 45.3% (1354/2989) had been vaccinated with PCV13. Fifty-five (1.8%) carried pneumococcus (45 identified by culture and 10 by real-time PCR only) and PCV13 serotypes were found in eight (0.3%) participants. Almost half (22/45) of pneumococcal isolates were not susceptible to at least one of the antibiotics tested. Vaccine-type carriage among vaccinated and unvaccinated individuals was similar (0.2% vs. 0.1%, respectively). Respiratory symptoms were associated with higher odds of pneumococcal colonization (adjusted OR: 2.1; 95% CI?=?1.1–3.8).Conclusions
Pneumococcal carriage among non-institutionalized adults ≥65?years of age was very low. Less than 0.5% of both vaccinated and unvaccinated individuals in our study carried vaccine-type serotypes. Over a decade of PCV vaccination of children likely led to indirect effects in adults. However, given the low vaccine-type carriage rates we observed in an already high PCV13 adult coverage setting, it is difficult to attribute our findings to the direct versus indirect effects of PCV13 on adult carriage. 相似文献10.